[1] Marx A, Pfister F, Schalke B, et al. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes [J]. Autoimmun Rev, 2013, 12(9): 875-884. [2] Cavalcante P, Le PR, Berrih-Aknin S, et al. The thymus in myasthenia gravis: Site of "innate autoimmunity" [J]. Muscle Nerve, 2011, 44(4): 467-484. [3] Buckley C, Douek D, Newsom-Davis J, et al. Mature, long-lived CD 4 + and CD 8 + T cells are generated by the thymoma in myasthenia gravis [J]. Ann Neurol, 2001, 50(1): 64-72. [4] Luther C, Poeschel S, Varga M, et al. Decreased frequency of intrathymic regulatory T cells in patients with myasthenia-associated thymoma [J]. J Neuroimmunol, 2005, 164(1-2): 124-128. [5] Marx A, Willcox N, Leite MI, et al. Thymoma and paraneoplastic myasthenia gravis [J]. Autoimmunity, 2010, 43(5-6): 413-427. [6] 陈玉萍,王卫,王中魁,等. 重症肌无力伴发胸腺瘤患者的临床特点分析[J]. 中华内科杂志, 2012, 51(8): 623-625. [7] 邢岩,崔丽英,管宇宙,等. 72例重症肌无力伴胸腺瘤的临床及神经电生理研究[J]. 中华医学杂志, 2007, 87(45): 3188-3191. [8] Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity [J]. Lancet Neurol, 2009, 8(5): 475-490. [9] Akaishi T, Yamaguchi T, Suzuki Y, et al. Insights into the classification of myasthenia gravis [J]. PLoS One, 2014, 9(9): e106757. [10] Nakajima J, Okumura M, Yano M, et al. Myasthenia gravis with thymic epithelial tumour: a retrospective analysis of a Japanese database [J]. Eur J Cardiothorac Surg, 2016, 49(5): 1510-1515. [11] Karasaki T, Murakawa T, Nagayama K, et al. New onset of myasthenia gravis 10 years after proton beam therapy for thymoma [J]. Gen Thorac Cardiovasc Surg, 2016, 64(5): 290-293. [12] Huang X, Liu WB, Men LN, et al. Clinical features of myasthenia gravis in southern China: a retrospective review of 2,154 cases over 22 years [J]. Neurol Sci, 2013, 34(6): 911-917. [13] Romi F. Thymoma in myasthenia gravis: from diagnosis to treatment [J]. Autoimmune Dis, 2011, 2011: 474512. [14] Romi F, Aarli JA, Gilhus NE. Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features [J]. Eur J Neurol, 2007, 14(6): 617-620. [15] Romi F, Skeie GO, Aarli JA, et al. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies [J]. Arch Neurol, 2000, 57(11): 1596-1600. [16] Chu XY, Xue ZQ, Wang RW, et al. Predictors of postoperative myasthenic crisis in patients with myasthenia gravis after thymectomy [J]. Chin Med J (Engl), 2011, 124(8): 1246-1250. [17] 刘宇,束余声. 胸腺切除术后发生肌无力危象危险因素的Meta分析[J]. 中华胸心血管外科杂志, 2015, 31(11): 660-664. [18] Liang T, Boulos MI, Murray BJ, et al. Detection of myasthenia gravis using electrooculography signals [J]. Conf Proc IEEE Eng Med Biol Soc, 2016, 2016: 896-899. [19] Nakata M, Kuwabara S, Kawaguchi N, et al. Is excitation-contraction coupling impaired in myasthenia gravis [J]. Clin Neurophysiol, 2007, 118(5): 1144-1148. [20] Jing F, Cui F, Chen Z, et al. Clinical and electrophysiological markers in myasthenia gravis patients [J]. Eur Neurol, 2015, 74(1-2): 22-27. [21] De Roxas RC, Bagnas MA, Baldonado JJ, et al. Clinical profile and outcome of postthymectomy versus non-thymectomy myasthenia gravis patients in the philippine general hospital: a 6-year retrospective study [J]. Front Neurol, 2016, 7: 96. [22] Bak V, Spalek P, Rajcok M, et al. Importance of thymectomy and prognostic factors in the complex treatment of myasthenia gravis [J]. Bratisl Lek Listy, 2016, 117(4): 195-200. [23] Spillane J, Hayward M, Hirsch NP, et al. Thymectomy: role in the treatment of myasthenia gravis [J]. J Neurol, 2013, 260(7): 1798-1801. [24] Nazarbaghi S, Amiri-Nikpour MR, Mahmodlou R, et al. Clinical outcomes of myasthenia gravis with thymoma and thymic hyperplasia undergoing extended transsternal thymectomy: a single-center experience [J]. N Am J Med Sci, 2015, 7(11): 503-508. [25] Mao Z, Hu X, Lu Z, et al. Prognostic factors of remission in myasthenia gravis after thymectomy [J]. Eur J Cardiothorac Surg, 2015, 48(1): 18-24. [26] Bak V, Spalek P, Rajcok M, et al. Importance of thymectomy and prognostic factors in the complex treatment of myasthenia gravis [J]. Bratisl Lek Listy, 2016, 117(4): 195-200. |